Published in Drugs Context on November 19, 2012
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | NCT00803374
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852) | NCT01174238
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | NCT01078961
Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. J Biomed Sci (2015) 0.80
Folated synperonic-cholesteryl hemisuccinate polymeric micelles for the targeted delivery of docetaxel in melanoma. Biomed Res Int (2015) 0.77
Metabolism under hypoxia in Tm1 murine melanoma cells is affected by the presence of galectin-3, a metabolomics approach. Springerplus (2014) 0.77
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget (2016) 0.76
Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett (2017) 0.75
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist (2009) 2.85
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol (2002) 2.57
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol (2006) 1.95
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89
New drugs in melanoma: it's a whole new world. Eur J Cancer (2011) 1.88
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res (2000) 1.70
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res (2004) 1.51
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev (2005) 1.46
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res (2011) 1.46
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev (2007) 1.37
BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol (2006) 1.35
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol (2012) 1.33
CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33
A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell (2002) 1.32
Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist (2007) 1.30
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol (2006) 1.29
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res (2011) 1.28
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer (2006) 1.27
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Temozolomide and unusual indications: review of literature. Cancer Treat Rev (2012) 1.24
Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc (2001) 1.23
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev (2008) 1.22
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Targeted therapy in brain metastasis. Curr Opin Oncol (2012) 1.21
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer (2010) 1.15
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer (2012) 1.09
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs (2008) 1.08
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther (2012) 1.07
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res (2001) 1.06
Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol (2005) 1.04
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene (2012) 1.04